Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Autor:	Bo Zhao, Laura S. Wood, Karen James, Brian I. Rini
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Case Reports in Oncological Medicine, Vol 2015 (2015)
Druh dokumentu:	article
ISSN:	2090-6706 2090-6714
DOI:	10.1155/2015/817578
Popis:	Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/42e72c5389024f66b21e24646a1cef7b Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF